Home » Stocks » Verastem

Verastem, Inc. (VSTM)

Stock Price: $1.48 USD 0.00 (0.00%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $1.47 -0.01 (-0.68%) Aug 7, 7:59 PM

Stock Price Chart

Key Info

Market Cap 240.55M
Revenue (ttm) 20.84M
Net Income (ttm) -149.10M
Shares Out 158.60M
EPS (ttm) -1.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $1.48
Previous Close $1.48
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.49
Day's Range 1.46 - 1.52
Day's Volume 2,196,333
52-Week Range 0.83 - 4.67

More Stats

Market Cap 240.55M
Enterprise Value 125.95M
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 158.60M
Float 134.49M
EPS (basic) -1.84
EPS (diluted) -1.79
FCF / Share -0.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 8.65M
Short Ratio 1.28
Short % of Float 6.13%
Beta 1.09
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 11.54
PB Ratio 1.77
Revenue 20.84M
Operating Income -125.34M
Net Income -149.10M
Free Cash Flow -34.00M
Net Cash 114.60M
Net Cash / Share 0.71
Gross Margin 77.82%
Operating Margin -601.43%
Profit Margin -715.40%
FCF Margin -163.15%
ROA -33.84%
ROE -141.03%
ROIC -92.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.00*
(170.27% upside)
Low
3.00
Current: $1.48
High
5.00
Target: 4.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue17.4626.72-------
Revenue Growth-34.67%--------
Gross Profit14.6526.13-------
Operating Income-132-94.78-67.80-37.00-58.20-53.61-41.40-32.23-13.70
Net Income-149-72.43-67.80-36.44-57.87-53.37-41.20-31.98-13.68
Shares Outstanding74.5864.9638.4236.9935.9325.8022.6818.771.30
Earnings Per Share-2.00-1.37-1.76-0.99-1.61-2.07-1.82-1.70-10.59
Operating Cash Flow-139-74.52-57.31-29.48-45.56-36.90-26.31-22.60-9.37
Capital Expenditures-0.01-23.43--0.04-0.21-2.43-0.06-0.31-0.79
Free Cash Flow-139-97.94-57.31-29.52-45.77-39.33-26.36-22.91-10.16
Cash & Equivalents11125086.6781.0611092.8810156.6647.90
Total Debt10412014.83------
Net Cash / Debt6.7012971.8481.0611092.8810156.6647.90
Assets14527789.7983.6311398.6512592.9259.04
Liabilities13815332.1111.3310.639.887.822.4671.80
Book Value7.1712457.6872.3010288.7711790.47-12.77
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Verastem, Inc.
Country United States
Employees 135
CEO Brian M. Stuglik

Stock Information

Ticker Symbol VSTM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VSTM
IPO Date January 27, 2012

Description

Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is headquartered in Needham, Massachusetts.